Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2017

View Archived Issues

FDA awards orphan drug designation to Cascadian's tucatinib

AzurRx reports initial data from ongoing phase IIa trial of MS-1819-SD

Synergys Biotherapeutics receives grant to support SYN-001 development

Diamyd to design first clinical trial of Remygen

NIDA grant supports Camino Pharma's development of compounds for substance use disorders

New lung cancer study to utilize Inivata's InVision liquid biopsy platform

Safety explored in first-in-human study of KHK-4083, a monoclonal antibody targeting OX40

Eidos Therapeutics doses first cohort in AG-10 phase I study

Topline results from phase I/II study of SciFluor's SF-0166 for DME

Inhaled sodium cromoglycate formulation PA-101 reduces cough in IPF patients

Villin-1 as a biomarker of intestinal ischemia reperfusion injury

Achaogen awarded contract for development of C-Scape

Protagenic Therapeutics' PT-00114 shows efficacy in animal models

GlaxoSmithKline divulges CD73 inhibitors

FDA gives Emergency Use Authorization to Chembio for DPP Zika system test

Merck & Co. patents novel monobactam derivatives for bacterial infections

Raze Therapeutics identifies 3-PGDH inhibitors

Global Alliance for TB Drug Development patents compounds for tuberculosis

New York University discloses Wnt signaling inhibitors

FDA grants orphan drug designation to rimeporide for Duchenne muscular dystrophy

SI-613 begins phase II trial in Japan for enthesopathy

FDA approves Verzenio in breast cancer

Japanese orphan drug designation for olaparib for BRCA-positive breast cancer

First subject enrolled in phase III study of TRC-101 in chronic kidney disease

Quidel announces progress in acquisition of Alere's BNP business

FDA grants priority review to Amitiza sNDA for pediatric functional constipation

TLR3 identified as novel target for preventing cardiac ischemia reperfusion injury

Phase Ib data do not support progression of PRX-003 for psoriasis

U.S. contract supports progression of InBios point-of-care diagnostic test for B. anthracis

Zynerba reports promising data from phase II trial of ZYN-002 for fragile X syndrome

Curemark completes enrollment in phase III trial of CM-AT in autism

FDA grants priority review to Linhaliq NDA

FDA priority review for Perjeta sBLA for adjuvant treatment of HER2-positive early breast cancer

NIAID grant supports development of thermostable trivalent Ebola vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026